



Un-audited
Financial Statements
For the 3rd Quarter
Ended 30 September 2025

A large, detailed dandelion seed head is the central focus, with its green stem extending from the bottom. The seed head is blowing, with many seeds captured in mid-air, creating a sense of motion and lightness. The background is a clear, vibrant blue sky with some wispy clouds at the bottom. The overall mood is bright and optimistic.

**Enriching
Life**

CONTENTS

Company Information	2
Directors' Report	3-8
Condensed Interim Un-Consolidated Financial Statements	9
Condensed Interim Un-Consolidated Statement of Financial Position	10-11
Condensed Interim Un-Consolidated Statement of Profit or Loss	12
Condensed Interim Un-Consolidated Statement of Comprehensive Income	13
Condensed Interim Un-Consolidated Statement of Cash Flows	14-15
Condensed Interim Un-Consolidated Statement of Changes in Equity	16
Selected Notes to the Condensed Interim Un-consolidated Financial Statements	17
Condensed Interim Consolidated Financial Statements	29
Condensed Interim Consolidated Statement of Financial Position	30-31
Condensed Interim Consolidated Statement of Profit or Loss	32
Condensed Interim Consolidated Statement of Comprehensive Income	33
Condensed Interim Consolidated Statement of Cash Flows	34-35
Condensed Interim Consolidated Statement of Changes in Equity	36
Selected Notes to the Condensed Interim Consolidated Financial Statements	37

COMPANY INFORMATION

Board of Directors

Mr. Tariq Wajid
Chairman

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Tausif Ahmad Khan
Director

Tehmina Saeed Chaudhury
Director

Tauqir Ahmed Khan
Director

Dr. Amanullah Khan
Director

Chief Financial Officer

Ashfaq P. Alidina

Senior General Counsel & Company Secretary

Baqar Hasan

Head Internal Auditor

Hamza Bilal

Registered Office and Plant

17.5 Kilometer Multan Road,
Lahore - 53700, Pakistan
UAN: +9242111000465
Fax : +92 42 3751 0037
E-mail :
corporate.affairs@highnoon.com.pk;
investor.relations@highnoon.com.pk
Web : www.highnoon-labs.com

Corporate Office

901-9th floor, Tricon Corporate Center
73 -E, Jail Road, Lahore
UAN : +92 304 111 0465
Ph: +924235158051-2

Legal Advisor

Raja Muhammad Akram & Co.

Tax Advisor

Yousuf Islam & Associates

Auditors

BDO Ebrahim & Co.
Chartered Accountants

Shares Registrar

Corplink (Pvt.) Ltd
Wings Arcade,
1-K Commercial,
Model Town, Lahore.
Tel: +92 42 3591 6714, 3591 6719
Fax: +92 42 3586 9637

Audit Committee

Dr. Amanullah Khan Chairman

Tehmina Saeed Chaudhury Member

Mr. Tariq Wajid Member

Tauqir Ahmed Khan Member

Human Resource and Remuneration Committee

Tariq Wajid Chairman

Dr. Adeel Abbas Haideri Member

Tehmina Saeed Chaudhury Member

Taufiq Ahmed Khan Member

Sustainability Committee

Tehmina Saeed Chaudhry Chairman

Dr. Adeel Abbas Haideri Member

Tauqir Ahmed Khan Member

Executive Committee

Dr. Adeel Abbas Haideri Chairman

Sajjad Hafeez Butt Member

Ashfaq P. Alidina Member

Azfar Abbas Haideri Member

Zulfiqar Zaidi Member

Shahnawaz Baig Member

I.T. Steering Committee

Taufiq Ahmed Khan Chairman

Dr. Adeel Abbas Haideri Member

Ashfaq P. Alidina Member

Sajjad Hafeez Butt Member

Zulfiqar Ali Zaidi Member

Shahnawaz Baig Member

Farhan Iftikhar Hashmi Member

Bankers

Habib Bank Limited
United Bank Limited
J.S Bank Limited
Allied Bank Limited
Habib Metropolitan Bank Limited
Meezan Bank Limited
MCB Bank Limited
First Habib Modaraba Limited
Standard Chartered Bank Limited
Bank Makramah Limited (formerly
Summit Bank Limited)
Bank Alfalah Limited
Mobilink Microfinance Bank Limited
Askari Bank Limited
National Bank of Pakistan Limited
Bank Al-Habib Limited
Dubai Islamic Bank Limited

DIRECTORS' REPORT TO THE SHAREHOLDERS

The Directors of Highnoon Laboratories Limited (the “Company” or “Highnoon”) are pleased to present their report, together with the un-audited condensed interim financial statements of your Company and the Group for the nine months ended on September 30, 2025.

Your Company stands among the well-established healthcare companies of Pakistan, focused on enriching lives and patient facilitation through manufacture, import, sale and marketing of pharmaceutical and related healthcare products.

OPERATING RESULTS

The financial performance of the Company during the nine months ended September 30, 2025, under review, is as follows:

	September 2025	September 2024
Key Financial Highlights	(Rupees in Millions)	
Sales	18,615	16,956
Gross Profit	10,313	8,396
Gross Profit %	55%	50%
Operating Profit	3,880	3,125
Operating Profit %	21%	18%
Finance Cost	(91)	(169)
Other Income	333	327
Profit before tax & levy	4,122	3,282
Tax & levy	(1493)	(922)
Profit after tax & levy	2,628	2,360
Other Comprehensive Income - Net of Tax	-	-
Total Comprehensive Income for the Year	2,628	2,360

PERFORMANCE OVERVIEW

Net sales surged by 9.78%, primarily driven by an optimal product mix and volume expansion and price-led growth, drawing continuing leverage from its diversified portfolio, enhanced pricing strategies and further strengthening its market positioning.

Consequently, Gross Margins expanded from 49.5% to 55.4%, reflecting a 23% growth as compared to corresponding period in 2024. Despite challenges being faced by Pharma Industry, Highnoon effectively mobilized operational and strategic efficiencies, capitalized on regulatory pricing shifts, and maintained strong market intelligence. This enabled the company to not only sustain but enhance profitability, achieving a 14% profit-to-sales ratio for the period and reflecting a growth of 11% in profit after taxes verses same period last year.

Highnoon has consistently aimed high and maintained a strong momentum towards achievement of key milestones. For gauging its performance, the Company makes use of various indicators like peer's position in relevant therapeutic class, industry growth and the impact of changes in laws/regulations on Company's performance. Key Performance Indicators are then formulated so proactively remedial actions can be taken in case of any variance with the actual performance at regular intervals.

EARNINGS PER SHARE

Based on unaudited condensed interim financial statements for nine months ended September 30, 2025, Basic Earnings Per Share (EPS) is Rs. 49.61 (2024: 44.54).

GROUP PERFORMANCE

The Directors are pleased to present the unaudited Condensed Interim Consolidated Financial Statements of Highnoon Laboratories Limited the ("Holding Company") and Curexa Health (Private) Limited, its wholly owned Subsidiary company ("the Subsidiary") together mentioned as ("the Group") for the nine months ended September 30, 2025.

The summarized financial performance of the Group during the nine months ended September 30, 2025, under review, is as follows:

	September 2025	September 2024
Key Financial Highlights	(Rupees in Millions)	
Profit before tax and levy	4,238	3,380
Tax & levy	(1,558)	(984)
Profit after tax and levy	2,681	2,396
Earning Per Share (Rs.)	50.59	45.22

FUTURE OUTLOOK

Pakistan is at a crossroads where, decisive, multi-faceted reforms and visionary leadership is needed to unlock economic potential and build resilience. Given the positive trend in inflation, Pakistan's macroeconomic outlook now reflects cautious optimism, underpinned by fiscal consolidation and external sector stabilization.

Nonetheless, there are challenges posed by the regulatory landscape due to its complexity and lack of transparency which underscores the need for a consistent policy framework and streamlined regulatory procedures to ensure the sector's optimal contribution towards the well-being of the people of Pakistan.

Highnoon's focus on operational efficiencies, strategic portfolio diversification, and market expansion will be instrumental in sustaining profitability amid an evolving economic landscape.

ACKNOWLEDGMENT

The Board of Directors extends its sincere gratitude to all employees for their unwavering dedication and commitment throughout the period. We also acknowledge the invaluable support of our shareholders, customers, and partners, whose trust and collaboration have been pivotal in driving strategic objectives and sustainable growth. Looking ahead, we remain committed to upholding the highest standards of corporate governance and delivering long-term value to all our stakeholders.

AUTHORIZATION

The Board, in compliance with the requirement of Section 227(5) of Companies Act 2017, authorized the Chief Executive Officer and a director to sign the Directors' Report on behalf of the Board.

For, and on behalf of the Board



Dr. Adeel Abbas Haideri
Chief Executive Officer



Taufiq Ahmed Khan
Director

Lahore: September 30th, 2025

اظہار تشکر

بورڈ آف ڈائریکٹرز اپنے تمام ملازمین کا دل سے شکریہ ادا کرتا ہے جنہوں نے پورے نو ماہی کے دوران اپنی غیر متزلزل لگن اور عزم کا مظاہرہ کیا۔ ہم اپنے شیئر ہولڈرز، صارفین اور شرکاء کے ساتھ اپنی قیمتی تعاون کا بھی شکریہ ادا کرتے ہیں جن کے اعتماد اور شراکت نے ہماری اسٹریٹجک مقاصد اور پائیدار ترقی کو آگے بڑھانے میں اہم کردار ادا کیا۔ آئندہ کی جانب، ہم کارپوریٹ گورننس کے اعلیٰ ترین معیارات کو برقرار رکھنے اور اپنے تمام اسٹیک ہولڈرز کے لیے طویل مدتی قدر فراہم کرنے کے لیے عزم میں ہیں۔

اجازت نامہ

بورڈ نے کمپنیز ایکٹ 2017 کے سیکشن 227(5) کی ضروریات کے تحت، چیف ایگزیکٹو آفیسر اور ایک ڈائریکٹر کو بورڈ کی طرف سے ڈائریکٹرز کی رپورٹ پر دستخط کرنے کا اختیار دیا ہے۔

منجانب بورڈ آف ڈائریکٹرز



توفیق احمد خان
ڈائریکٹر



ڈاکٹر عدیل عباس حیدری
چیف ایگزیکٹو آفیسر
لاہور: 30 ستمبر 2025

ہائی نون نے ہمیشہ بلند مقاصد مقرر کیے ہیں اور اہم سنگ میلوں کے حصول کے لیے مضبوط رفتار برقرار رکھی ہے۔ کارکردگی کا اندازہ لگانے کے لیے، کمپنی مختلف پیمانے استعمال کرتی ہے جن میں متعلقہ علاج کے شعبے میں ہم مرتبہ اداروں کی حیثیت، صنعت کی مجموعی نمو، اور قوانین و ضوابط میں ہونے والی تبدیلیوں کا کمپنی کی کارکردگی پر اثر شامل ہے۔ بعد ازاں کلیدی کارکردگی کے پیمانے وضع کیے جاتے ہیں تاکہ حقیقی کارکردگی میں کسی بھی انحراف کی صورت میں بروقت اصلاحی اقدامات کیے جاسکیں اور کارکردگی کا باقاعدہ جائزہ لیا جاسکے۔

فی شیئر آمدنی

30 ستمبر 2025 کو ختم ہونے والے نو ماہ کے لیے غیر آڈٹ شدہ عبوری مالیاتی بیانات کی بنیاد پر، فی شیئر آمدنی 49.61 روپے رہی، جو گزشتہ سال 44.54 روپے تھی۔

گروپ کی کارکردگی

ڈائریکٹرز کو خوشی محسوس ہو رہی ہے کہ وہ ہائی نون لیبارٹریز لمیٹڈ ("ہولڈنگ کمپنی") اور اس کی مکمل ملکیتی ذیلی کمپنی کیوریکسا ہیلتھ (پرائیویٹ) لمیٹڈ ("ذیلی کمپنی")، جنہیں مجموعی طور پر ("گروپ") کہا جاتا ہے، کی غیر آڈٹ شدہ جامع عبوری مالیاتی بیانات 30 ستمبر 2025 کو ختم ہونے والی نو ماہی کے لیے پیش کر رہے ہیں۔

30 ستمبر 2025 کو ختم ہونے والی نو ماہی کیلئے گروپ کی مالی کارکردگی کا خلاصہ کے درج ذیل ہے۔

30 ستمبر 2025	30 ستمبر 2024	
روپے (000,000)		
4,238	3,380	قبل از ٹیکس اور لیوی منافع
(1,558)	(984)	ٹیکس اور لیوی
2,681	2,396	بعد از ٹیکس منافع
50.59	45.22	فی شیئر آمدنی

مستقبل پر ایک نظر

پاکستان ایک اہم مرحلے پر ہے جہاں اقتصادی صلاحیت کو اجاگر کرنے اور مضبوطی پیدا کرنے کے لیے فیصلہ کن، کثیر الجہتی اصلاحات اور بصیرت والی قیادت کی ضرورت ہے۔ مہنگائی میں کمی کے مثبت رجحان کو مد نظر رکھتے ہوئے، پاکستان کے ٹیکس و اٹا ملک منظر نامے میں اب محتاط امید کی علامات دکھائی دے رہی ہیں، جو مالی استحکام اور بیرونی شعبے کی استحکام پر مبنی ہے۔

بہر حال، مضبوطی کے منظر نامے میں پیچیدگی اور شفافیت کی کمی کے باعث کچھ چیلنجز موجود ہیں، جو اس بات کو اجاگر کرتے ہیں کہ ایک مستقل پالیسی فریم ورک اور مربوط ضوابطی طریقہ کار کی ضرورت ہے تاکہ اس شعبے کا پاکستان کے عوام کی فلاح و بہبود کے لیے بہترین کردار کو یقینی بنایا جاسکے۔

ہائی نون کی توجہ آپریشنل کارکردگیوں، اسٹریٹجک پورٹ فولیو کی متنوع بنانے اور مارکیٹ کی توسیع پھر کو زہے، جو بدلتے ہوئے اقتصادی منظر نامے میں منافع کو برقرار رکھنے میں اہم کردار ادا کرے گی۔

ڈائریکٹر رپورٹ

ہائون لیباریٹریز لمیٹڈ کے ڈائریکٹر 30 ستمبر 2025 کو ختم ہونے والی نو ماہی کے لئے کمپنی اور گروپ کی رپورٹ بمعہ غیر آڈٹ شدہ مختصر عبوری مالیاتی گوشوارے پیش کرتے ہوئے خوش محسوس کرتے ہیں۔

آپ کی کمپنی پاکستان کی معروف ہیلتھ کیئر کمپنیوں میں شامل ہے، دواسازی اور متعلقہ مصنوعات کی تیاری، درآمد، فروخت اور مارکیٹنگ کے ذریعے زندگیوں کو بہتر بنانے اور مریضوں کو سہولت فراہم کرنے پر مرکوز ہے۔

آپریٹنگ نتائج

کمپنی کی 30 ستمبر 2025 کو ختم ہونے والی نو ماہی کی غیر آڈٹ شدہ مالی کارکردگی درج ذیل ہے۔

30 ستمبر 2025	30 ستمبر 2024	
روپے (000,000)		
18,615	16,956	فروخت
10,313	8,396	گراس منافع
55%	50%	گراس منافع فیصد
3,880	3,125	آپریٹنگ منافع
21%	18%	آپریٹنگ منافع فیصد
(91)	(169)	مالی لاگت
333	327	دیگر آمدنی
4,122	3,282	ٹیکس اور لیوی سے پہلے منافع
(1493)	(922)	ٹیکس اور لیوی
2,628	2,360	ٹیکس اور لیوی کے بعد منافع
-	-	دیگر کپریٹینسز آمدن بعد از ٹیکس
2,628	2,360	سالانہ کل کپریٹینسز آمدن

کارکردگی کا جائزہ

خاص فروخت میں 9.78 فیصد اضافہ ریکارڈ کیا گیا، جو بنیادی طور پر بہتر مصنوعات کے امتزاج، پیداوار میں اضافے اور قیمتوں میں اضافے سے حاصل شدہ نمو کی بدولت ممکن ہوا۔ کمپنی نے اپنے متنوع مصنوعات کے پورٹ فولیو سے حاصل ہونے والے مسلسل فائدے، مؤثر قیمتوں کی حکمت عملی، اور مارکیٹ میں اپنی پوزیشن کو مزید مضبوط بنانے کے ذریعے اس نمو کو حاصل کیا۔

نتیجتاً، مجموعی منافع کا مارجن 49.5 فیصد سے بڑھ کر 55.4 فیصد ہو گیا، جو سال 2024 کی اسی مدت کے مقابلے میں 23 فیصد اضافہ ظاہر کرتا ہے۔ فارما انڈسٹری کو درپیش مشکلات کے باوجود، ہائی ٹون نے پیداواری اور حکمت عملی کی کارکردگی کو مؤثر انداز میں متحرک کیا، ریگولیٹری قیمتوں میں تبدیلیوں سے بھرپور فائدہ اٹھایا، اور مارکیٹ کی فہم کو برقرار رکھا۔ اس کے نتیجے میں کمپنی نہ صرف اپنا منافع برقرار رکھنے میں کامیاب رہی بلکہ اسے مزید بہتر بنایا، اور اس مدت کے دوران منافع اور فروخت کے تناسب 14 فیصد کا حاصل کیا، جو گزشتہ سال کی اسی مدت کے مقابلے میں منافع بعد از ٹیکس میں 11 فیصد اضافے کی عکاسی کرتا ہے۔



Un-Consolidated Condensed Interim Financial Statements

Highnoon Laboratories Limited
for the nine months ended 30 September 2025

Condensed Interim Un-Consolidated Statement of Financial Position As at 30 September 2025 (Un Audited)

		Un Audited 30 September 2025	Audited 31 December 2024
Note		------(Rupees)-----	
ASSETS			
Non-current assets			
Property, plant and equipment	5	3,551,762,255	3,346,874,631
Intangible assets		45,783,439	46,866,785
Long-term investment		325,000,000	200,000,000
Long-term deposits		44,214,362	24,916,894
Long-term loans and advances		147,920,898	63,899,529
		4,114,680,954	3,682,557,839
Current assets			
Stock in trade	6	5,437,560,286	4,135,824,753
Trade receivables	7	3,877,514,420	2,311,740,481
Advances, trade deposits and prepayments		989,844,031	535,985,033
Other receivables		178,356,095	148,510,886
Short-term investment	8	1,368,326,411	3,638,850,646
Tax refunds due from the Government		229,667,178	149,615,092
Cash and bank balances	9	778,569,953	1,459,206,965
		12,859,838,372	12,379,733,856
TOTAL ASSETS		16,974,519,327	16,062,291,695


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director


Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Financial Position As at 30 September 2025 (Un Audited)

		Un Audited 30 September 2025	Audited 31 December 2024
Note		------(Rupees)-----	
EQUITY AND LIABILITIES			
Share capital and reserves			
Authorized share capital			
100,000,000 (December 31, 2024: 100,000,000)			
		1,000,000,000	1,000,000,000
Ordinary shares of Rs. 10 each			
Issued, subscribed and paid up share capital	10	529,833,630	529,833,630
Capital reserves			
Surplus on revaluation of property, plant and equipment - net of tax		847,860,257	865,425,008
Revenue reserves			
Accumulated profit		10,352,527,726	9,825,907,063
Total Equity		11,730,221,613	11,221,165,701
Non-current liabilities			
Lease liabilities		247,469,324	70,062,585
Long-term loan - secured	11	3,397,567	318,819,789
Deferred tax liabilities		208,063,654	208,063,654
Deferred liabilities		163,420,328	403,793,433
		622,350,873	1,000,739,461
Current liabilities			
Trade and other payables		3,554,343,911	2,621,067,508
Contract liabilities		130,493,820	62,819,114
Unclaimed dividend		304,677,160	210,193,857
Current portion of long-term liabilities		74,500,607	196,306,054
Provision for taxation		557,931,343	-
Short term borrowings		-	750,000,000
		4,621,946,841	3,840,386,533
CONTINGENCIES AND COMMITMENTS			
	12		
TOTAL EQUITY AND LIABILITIES		16,974,519,327	16,062,291,695

The annexed notes from 1 to 21 form an integral part of these unconsolidated condensed interim financial statements.


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director



Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Profit or Loss (Un Audited)


For the nine months ended 30 September 2025

	Note	Nine Months Ended 30 September		Three Months Ended 30 September	
		2025	2024	2025	2024
		------(Rupees) -----		------(Rupees) -----	
Revenue from contracts with customers- net	13	18,614,843,018	16,956,083,422	6,575,586,343	5,924,398,442
Cost of revenue	14	(8,375,143,514)	(8,577,426,149)	(2,857,168,006)	(2,914,099,403)
Gross profit		10,239,699,504	8,378,657,273	3,718,418,337	3,010,299,039
Distribution, selling and promotional expenses		(5,067,607,599)	(4,243,778,797)	(1,876,789,080)	(1,571,852,991)
Administrative and general expenses		(1,063,957,082)	(703,372,310)	(386,288,496)	(245,441,147)
Other operating expenses		(227,950,543)	(306,818,996)	(47,958,135)	(103,897,052)
		(6,359,515,225)	(5,253,970,103)	(2,311,035,712)	(1,921,191,190)
Profit from operations		3,880,184,279	3,124,687,170	1,407,382,626	1,089,107,849
Other income	15	332,611,911	326,802,720	102,982,389	123,586,914
Finance costs		(91,126,361)	(169,048,482)	(37,002,185)	(56,477,920)
Profit before income tax and final tax		4,121,669,830	3,282,441,409	1,473,362,830	1,156,216,843
Final taxes		-	(10,178,417)	-	14,000,210
Profit before income tax		4,121,669,830	3,272,262,992	1,473,362,830	1,170,217,053
Taxation		(1,493,279,398)	(912,212,663)	(472,283,351)	(311,418,121)
Profit after tax for the period		2,628,390,432	2,360,050,329	1,001,079,479	858,798,932
Earnings per share - basic and diluted (Rupees)	16	49.61	44.54	18.89	16.21

The annexed notes from 1 to 21 form an integral part of these unconsolidated condensed interim financial statements.


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director


Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Comprehensive Income (Un Audited)

For the nine months ended 30 September 2025

	Nine Months Ended 30 September		Three Months Ended 30 September	
	2025	2024	2025	2024
	------(Rupees) -----		------(Rupees) -----	
Profit after tax for the period	2,628,390,432	2,360,050,329	1,001,079,479	858,798,932
Other comprehensive income				
Effect of deferred tax due to change in effective tax rate	-	-	-	-
Total comprehensive income for the period	2,628,390,432	2,360,050,329	1,001,079,479	858,798,932

The annexed notes from 1 to 21 form an integral part of these unconsolidated condensed interim financial statements.



Dr. Adeel Abbas Haideri
 Chief Executive Officer



Taufiq Ahmed Khan
 Director



Ashfaq P. Alidina
 Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Cash Flow (Un Audited)

For the nine months ended 30 September 2025

	Nine Months Ended 30 Septemebr	
	2025	2024
Note	----- (Rupees) -----	
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before income tax	4,121,669,830	3,282,441,409
Adjustments for non cash and other items:		
Depreciation of property, plant and equipment	216,069,963	149,794,658
Depreciation of right-of-use asset	11,576,481	69,757,320
Amortization of intangible assets	11,290,984	20,415,884
Gain on disposal of property plant and equipment	(35,502,805)	(16,168,681)
Exchange gain - net	(2,066,989)	(5,027,675)
Dividend income on short-term investment	(10,676,633)	(199,239,803)
Provision for slow moving and obsolete stocks	7,685,497	(14,059,223)
Provision for defined benefit obligation	376,528,691	45,222,248
Provision for Workers' Profit Participation fund	216,175,371	140,608,709
Provision for Workers' Welfare Fund	81,643,395	53,431,311
Provision for Central Research Fund	35,791,962	26,445,800
Allowance for expected credit losses	-	-
Finance costs	91,126,361	169,048,482
	999,642,278	440,229,030
Profit before working capital changes	5,121,312,107	3,722,670,439
Working capital changes:		
(Increase) / decrease in current assets:		
Inventories	(1,309,421,030)	768,042,298
Trade debts	(1,563,706,950)	(1,008,296,202)
Advances, trade deposits and prepayments	(453,858,998)	(433,790,071)
Other receivables	(4,845,209)	(14,458,937)
Tax refunds due from the Government	(80,052,086)	172,861,151
Increase / (decrease) in current liabilities:		
Trade and other payables	681,463,862	963,967,708
Contract liabilities	67,674,706	311,270,081
	(2,662,745,704)	759,596,028
Cash generated from operations	2,458,566,403	4,482,266,467
Income taxes paid	(935,348,055)	(690,616,035)
Gratuity paid	(616,901,796)	(59,570,044)
Finance costs paid	(91,126,361)	(169,048,482)
Workers' Welfare Fund paid	(81,798,187)	-
Central research fund paid	-	(35,833,877)
	(1,725,174,399)	(955,068,438)
Net cash generated from operating activities	A 733,392,004	3,527,198,029

Condensed Interim Un-Consolidated Statement of Cash Flow (Un Audited)

For the nine months ended 30 September 2025

		Nine Months Ended 30 Septemebr	
	Note	2025	2024
		------(Rupees)-----	
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(664,316,596)	(560,942,971)
Purchase of intangible assets		(10,207,638)	(17,341,759)
Increase in long-term investment		(125,000,000)	-
Decrease / (Increaease) in long term advances		15,978,631	(25,281,106)
Loan (to) / from subsidiary - net		(125,000,000)	10,000,000
Short term investments - net		2,270,524,235	(40,931,730)
Long term deposits - net		(19,297,468)	(2,037,943)
Dividend income on short term investments		10,676,633	-
Proceeds from disposal of property plant and equipment		267,285,333	46,062,227
Net cash generated from investing activities	B	1,620,643,130	(590,473,282)
CASH FLOWS FROM FINANCING ACTIVITIES			
Lease liabilities - net		180,601,292	(199,344,194)
Long term loan - net		(440,422,222)	(34,172,222)
Dividend paid		(2,024,851,217)	(1,567,428,771)
Net cash used in financing activities	C	(2,284,672,147)	(1,800,945,187)
Net increase in cash and cash equivalents	(A+B+C)	69,362,988	1,135,779,560
Cash and cash equivalents at beginning of the period		709,206,965	40,443,641
Cash and cash equivalents at end of the period	9.2	778,569,953	1,176,223,201

The annexed notes from 1 to 21 form an integral part of these condensed interim consolidated financial statements.


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director


Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Changes in Equity (Un Audited)

For the nine months ended 30 September 2025

Statement of Changes in Equity (Un Audited)					
For the nine months ended 30 September 2025					
	Issued, subscribed and paid-up capital	Capital Reserves	Revenue reserves		Total
			Revaluation Surplus on operating fixed asset	General reserve	
----- Rupees -----					
Balance as at January 01, 2024 - (audited)	529,833,630	899,339,441	114,000,000	8,053,526,233	9,596,699,304
Total comprehensive income for the period ended September 30, 2024	-	-	-	2,360,050,329	2,360,050,329
Surplus transferred to accumulated profit					
Incremental depreciation relating to surplus on revaluation - net of tax	-	(31,415,733)	-	31,415,733	-
Transaction with owners, recorded directly in equity					
Final dividend @ Rs. 30 per share for the year ended December 31, 2023	-	-	-	(1,589,500,893)	(1,589,500,893)
Balance as at September 30, 2024 - (un-audited)	529,833,630	867,923,708	114,000,000	8,855,491,402	10,367,248,740
Balance as at January 01, 2025 - (audited)	529,833,630	865,425,008	114,000,000	9,711,907,063	11,221,165,701
Total comprehensive income for the period ended September 30, 2025	-	-	-	2,628,390,432	2,628,390,432
Surplus transferred to accumulated profit					
Incremental depreciation relating to surplus on revaluation - net of tax	-	(17,564,751)	-	17,564,751	-
Transaction with owners, recorded directly in equity					
Final dividend @ Rs. 40 per share for the year ended December 31, 2024	-	-	-	(2,119,334,520)	(2,119,334,520)
Balance as at September 30, 2025 - (un-audited)	529,833,630	847,860,257	114,000,000	10,238,527,726	11,730,221,613

The annexed notes from 1 to 21 form an integral part of these unconsolidated condensed interim financial statements.



Dr. Adeel Abbas Haideri
Chief Executive Officer



Taufiq Ahmed Khan
Director



Ashfaq P. Alidina
Chief Financial Officer

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

1. THE COMPANY AND ITS OPERATIONS

Highnoon Laboratories Limited ("the Company") was incorporated in Pakistan under the Companies Act, 2017 ("the Act") in March 1984 and its shares are quoted on Pakistan Stock Exchange since November 1994. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and allied consumer products. The registered office of the Company and its manufacturing facility is situated at 17.5 KM, Multan Road, Lahore.

Geographical location and addresses of major business units of the Company are as under:

Business Units	Geographical Location	Address
Registered office / Manufacturing facility	Lahore	17.5 KM, Multan Road, Lahore
Corporate Office	Lahore	Office# 901 Tricon Corporate Centre, Jail Road, Lahore.
Sales office	Karachi	202 Anam Empire, Block 7/8 KCHS,Shahrah e Faisal, Karachi
Sales office	Lahore	14-G, Block L, Gulberg - III, Lahore
Sales office	Rawalpindi	132 Hali Road, Westridge - I, PeshawarRoad, Rawalpindi

2. BASIS OF PREPARATION

2.1 Statement of compliance

These unconsolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. These accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34 - Interim Financial Reporting, issued by the International Accounting Standard Board (IASB) as notified under the Companies Act, 2017; and
- Provision and directives issued under the Companies Act, 2017 ("the Act").

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

2.2 These unconsolidated condensed interim financial statements are un-audited and are being submitted to the shareholders as required under Section 237 of the Act and the Listed Companies (Code of Corporate Governance) Regulations 2019. These unconsolidated condensed interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with unconsolidated financial statements of the Company for the year ended December 31, 2024. Comparative unconsolidated condensed interim statement of financial position is stated from annual audited unconsolidated financial statements as of December 31, 2024, whereas comparatives for unconsolidated condensed interim statement of profit or loss and other comprehensive income, unconsolidated condensed interim statement of changes in equity and unconsolidated condensed interim statement of cash flows are extracted from unconsolidated condensed interim financial statements of the Company for the nine months ended September 30, 2024.

2.3 The unconsolidated condensed interim financial statements have been prepared under the historical cost convention, except for certain classes of operating fixed assets (as mentioned in unconsolidated financial statements of the Company for the year ended December 31, 2024) and certain employees' retirement benefits which are measured at fair value and present value, respectively. These unconsolidated condensed interim financial statements are prepared in Pak Rupees, which is the functional currency of the Company. Figures have been rounded off to the nearest Pak rupee unless otherwise stated.

2.4 Provisions in respect of Workers' Welfare Fund, Workers' Profit Participation Fund and taxation are estimated based on management judgment and prevailing laws; these are subject to final adjustments in the annual audited financial statements.

3. USE OF ESTIMATES AND JUDGEMENTS

The preparation of these unconsolidated condensed interim financial statements, in conformity with accounting and reporting standards as applicable in Pakistan requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Actual results may differ from the estimates. During the preparation of these unconsolidated condensed interim financial statements, the significant judgements made by management in applying the Company's accounting policies and the key sources of estimation and assumptions are consistent with those that were applied to the audited unconsolidated financial statements of the Company for the year ended December 31, 2024.

4. MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies adopted in the preparation of these unconsolidated condensed interim financial statements are consistent with those followed in the preparation of the Company's annual unconsolidated financial statements for the year ended December 31, 2024 except for the policies mentioned and the adoption of amendments to approved accounting and reporting standards as applicable in Pakistan which became effective for the current period as disclosed in Note 4.1 to these unconsolidated condensed interim financial statements. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

4.1 Changings in accounting standard interpretations and pronouncements

a) New standards, interpretations, amendments and improvements effective during current period

Certain standards, amendments and interpretations to approved accounting standards are effective for accounting periods beginning on January 01, 2025, but are considered not to be relevant or to have any significant effect on the Company's operations (although they may affect the accounting for future transactions and events) and are, therefore, not detailed in these unconsolidated condensed interim financial statements.

b) Standards, interpretation and amendments to approved accounting standards that are not yet effective

In addition to the above standards and amendments, improvements to various accounting standards and conceptual framework have also been issued by the IASB. Such improvements are generally effective for accounting periods beginning on or after January 01, 2025. The Company expects that such improvements to the standards will not have any material impact on the Company's unconsolidated condensed interim financial statements in the period of initial application.

		Un Audited 30 September 2025	Audited 31 December 2024
	Note	----- (Rupees) -----	
5.	PROPERTY, PLANT AND EQUIPMENT		
		Operating fixed assets :	
	5.1	2,943,697,492	3,080,711,613
	5.1	251,333,384	89,084,423
		3,195,030,876	3,169,796,036
	5.1	356,731,379	177,078,595
		3,551,762,255	3,346,874,631

		Operating owned fixed assets	Right of use assets	Capital work in progress
5.1	Opening	3,080,711,613	89,084,423	177,078,595
	Additions	117,541,714	216,851,130	329,923,752
	Transfers/Disposals	(38,485,871)	(43,025,688)	(150,270,968)
	Depreciation for the Period	(216,069,963)	(11,576,481)	-
		2,943,697,492	251,333,384	356,731,379

Notes to the Condensed Interim
Un-Consolidated Financial Statements (Un Audited)
For the nine months ended 30 September 2025

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		------(Rupees) -----	
6 STOCK IN TRADE			
Raw materials:			
In hand		2,798,605,447	1,987,657,055
In transit		920,022,970	158,618,913
With third party		171,145,230	158,952,120
		3,889,773,647	2,305,228,088
 Packing material		759,009,438	748,530,418
Stores, spare parts and loose tools		150,077,271	81,173,502
 Work in process		370,974,852	451,785,182
 Finished goods:			
Trading -in hand		75,259,402	81,276,281
Manufactured		394,275,483	661,955,592
		469,534,885	743,231,873
		5,639,370,093	4,329,949,063
Less: Provision for slow moving and obsolete items		(201,809,807)	(194,124,310)
		5,437,560,286	4,135,824,753
 7 TRADE RECEIVABLES			
Foreign		103,410,306	120,550,269
Local		3,831,750,112	2,248,836,211
		3,935,160,419	2,369,386,480
Less: allowance for expected credit losses (ECL)		(57,645,999)	(57,645,999)
		3,877,514,420	2,311,740,481

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		------(Rupees) -----	
7.1	Allowance for expected credit losses		
	Opening balance	57,645,999	22,372,807
	Charged / (reversal) during the period / year	7.1.1 -	35,273,192
		57,645,999	57,645,999

8. SHORT-TERM INVESTMENT

Investments at fair value through profit or loss

Mutual funds - fair value through profit and loss	8.1	1,176,150,455	3,471,920,933
Term deposit receipts - at amortization cost	8.2	192,175,956	166,929,713
		1,368,326,411	3,638,850,646

8.1 Set out below is the movement during the period / year:

Balance at the beginning of the period / year		3,471,920,933	1,699,124,325
Additions during the period / year		2,708,921,850	4,383,230,301
Redemption during the period / year		(5,248,178,117)	(2,847,386,088)
Realized gain on redemption of investment during the period / year		84,043,829	79,159,430
Un-realized (loss) / gain on remeasurement of investments during the period / year		159,441,960	157,792,965
Closing fair value of short-term investment		1,176,150,455	3,471,920,933

8.2 These represents investments in term deposit receipts. They carry average profit at the rate of ranging from 10.00% - 16.00% (December 31, 2024: 11.25% - 21.00%) with maturity up to November 22, 2025.

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		------(Rupees) -----	
9	CASH AND BANK BALANCES		
	Cash and imprest	763,228	630,394
	Cash as banks:		
	Current accounts		
	-Local currency	126,932,556	1,035,137,688
	-Foreign currency	155,715,662	75,337,262
		282,648,218	1,110,474,950
	Saving accounts	9.1 495,158,506	348,101,621
		778,569,953	1,459,206,965

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

9.1 These represent saving accounts which carry average profit at the rate ranging from 6.46% to 9.00% (December 31, 2024: 9.21% to 20.10%).

9.2 Cash and cash equivalents

The above figures of cash and bank balances reconcile to the amount of cash and cash equivalents shown in the statement of cashflows at the end of financial year as follows:

Note	Un Audited 30 September 2025	Audited 31 December 2024
	----- (Rupees) -----	
Cash and bank balances	778,569,953	1,459,206,965
Short - term borrowings	-	(750,000,000)
Cash and cash equivalents as per statement of cashflows	778,569,953	709,206,965

10. ISSUED, SUBSCRIBED AND PAID UP SHARE CAPITAL

5,905,000 (December 31, 2024: 5,905,000) ordinary shares of Rs. 10 each fully paid in cash	59,050,000	59,050,000
95,000 (December 31, 2024: 95,000) ordinary shares of Rs.10 each issued for consideration other than cash	950,000	950,000
46,983,363 (December 31, 2024: 46,983,363) ordinary shares of Rs. 10 each issued as bonus shares	469,833,630	469,833,630
	529,833,630	529,833,630

11 LONG-TERM LOAN - SECURED

Long-term loan	7,293,863	447,716,085
Less: Current portion shown under current liabilities	(3,896,296)	(128,896,296)
	3,397,567	318,819,789

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		------(Rupees) -----	
11.1	The movement of Long-term loan is as follows:		
Opening balance	11.1.1 & 11.1.2	447,716,085	714,112,381
Addition during the period / year:		-	-
Loan obtained during the period / year		-	-
Less: deferred grant recognized		-	-
Principal payments made during the period / year		(440,422,222)	(266,396,296)
		7,293,863	447,716,085
Current portion shown under current liabilities		(3,896,296)	(128,896,296)
Closing balance		3,397,567	318,819,789

11.1.1 This includes loan from Meezan Bank Limited taken in year 2023 to meet the long term financing needs having sanctioned limit of Rs. 500 million and carries markup at the rate of 3 month KIBOR + 0.1% per annum payable quarterly, whereas the principal is repayable in 16 equal quarterly instalments commenced after a grace period of one year from September 2024. This facility is secured against first pari passu charge over all present and future plant and machinery. This loan has been early settled and repaid in full in current period.

11.1.2 This includes loan obtained from MCB Bank Limited under facility for setting up solar based power project under SBP financing scheme for renewable Energy having sanctioned limit of Rs. 50 million (2024: Rs. 50 million) and carries markup at the rate of 2% + 0.5% per annum payable quarterly (2024: 2% + 0.5%) whereas principal is repayable in 27 equal quarterly instalments starting from December 10, 2022. This facility is secured against lien on mutual fund up to Rs. 67 million placed in MCB-Arif Habib Savings and Investment Limited. The loan has been measured at its fair value in accordance with IFRS 9 (Financial Instruments) using effective interest rate of 3M KIBOR at respective draw down date. The difference between fair value of loan and loan proceeds has been recognised as deferred grant as per requirements of IAS 20 (Accounting for Government grants and disclosure of Government assistance) and as per Circular 11/2020 issued by the Institute of Chartered Accountants of Pakistan.

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

12. CONTINGENCIES AND COMMITMENTS

12.1 Contingencies

12.1.1 There have been no significant changes in other contingencies as reported in the annual audited unconsolidated financial statements of the Company for the year ended December 31, 2024.

12.1.2 The Assistant Commissioner Inland Revenue ('ACIR') has issued an order dated June 30, 2025 u/s 122 of the Income Tax Ordinance, 2001, in respect of tax year 2019, creating a demand amounting to Rs 845.706 million. The Company has preferred an appeal before Commissioner Inland Revenue, Appeals ('CIR(A)') against this order, on July 26, 2025, which is pending adjudication. The provision has not been recognised by the Company, as the management expects a favourable outcome.

12.1.3 There are several claims that have been lodged against the Company. The quantum of potential liability cannot be estimated reliably. The Company is hopeful of a favorable outcome, therefore, no provision has been recognized in these unconsolidated condensed interim financial statements.

		Un Audited 30 September 2025	Audited 31 December 2024
Note		----- (Rupees) -----	
12.2 Commitments			
	Commitments against irrevocable letters of credit include:		
	Letter of credit	1,542,899,465	963,000,541
	Bank contracts	709,545,816	270,379,501
	Ijarah rentals	88,956,224	-
		2,341,401,505	1,233,380,042

12.2.1 Future payments under Ijarah:

Within one year	25,016,505	-
After one year but not more than 5 years	63,939,719	-
	88,956,224	-

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

13. REVENUE FROM CONTRACTS WITH CUSTOMERS- NET

13.1 Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contracts with customers :

	Un-audited			
	Nine Months Ended 30 September		Three Months Ended 30 September	
	2025	2024	2025	2024
	----- (Rupees) -----			
Trading and manufactured products:				
Local	19,995,041,604	18,614,572,980	6,888,122,614	5,995,794,519
Export	1,531,682,021	1,551,855,766	676,015,467	575,058,000
	21,526,723,626	20,166,428,747	7,564,138,082	6,570,852,520
Toll manufacturing	614,707,380	516,422,734	243,504,514	175,082,401
Less:				
Sales tax	(179,894,168)	(182,566,268)	(52,133,540)	(71,798,160)
Sales return	(501,171,741)	(550,414,985)	(236,351,063)	(96,340,186)
Trade discount	(2,845,522,080)	(2,993,786,805)	(943,571,649)	(653,398,132)
	18,614,843,018	16,956,083,422	6,575,586,343	5,924,398,442

	Un-audited Nine Months Ended 30 September	
	2025	2024
	----- (Rupees) -----	
13.2 Geographical information		
Pakistan	17,083,728,249	15,407,024,327
Afghanistan	1,138,469,885	1,146,988,341
Cambodia	18,883,757	10,808,449
France	69,098,735	128,716,059
Gambia	-	2,029,002
Iraq	14,069,700	40,880,365
Kenya	6,177,926	55,914,476
Mauritius	1,052,637	1,919,209
Sri Lanka	70,701,337	34,843,782
Sudan	15,668,514	8,274,295
Tajikistan	-	3,678,444
Tanzania	-	4,503,993
Turkmenistan	14,260,472	-
United Arab Emirates	177,414,849	102,588,943
Zambia	5,316,958	7,913,737
	18,614,843,018	16,956,083,422

Notes to the Condensed Interim
Un-Consolidated Financial Statements (Un Audited)
For the nine months ended 30 September 2025

		Un-audited			
		Nine Months Ended 30 September		Three Months Ended 30 September	
		2025	2024	2025	2024
----- (Rupees) -----					
14	COST OF REVENUE				
	Opening stock of finished goods	743,231,873	931,608,898	715,614,475	294,972,606
	Cost of goods manufactured	7,260,403,818	7,385,207,652	2,286,377,015	2,860,744,896
	Purchased finish products	841,042,708	701,583,712	324,711,401	199,356,014
	Available stock for sale	8,844,678,399	9,018,400,262	3,326,702,891	3,355,073,516
	Closing stock of finished goods	(469,534,885)	(440,974,113)	(469,534,885)	(440,974,113)
	Cost of sales	8,375,143,514	8,577,426,149	2,857,168,006	2,914,099,403

		Un-audited Nine Months Period Ended 30 September	
		2025	2024
----- (Rupees) -----			
15	OTHER INCOME		
	Income from financial assets:		
	Return on deposits	6,221,297	4,653,230
	Profit on Term Deposit Receipts	21,477,305	59,432,166
	Dividend income on short-term investment	10,676,633	199,239,803
	Unrealized gain on re-measurement of short term investment to fair value	159,441,960	-
	Realized gain on redemption of short term investment	84,043,829	35,170,175
	Interest on loan to subsidiary	3,997,055	305,142
	Exchange gain - net	2,066,989	6,395,407
		287,925,068	305,195,923
	Income from non-financial assets:		
	Gain on disposal of property, plant and equipment	35,502,805	16,168,681
	Royalty income from subsidiary	8,881,846	-
	Scrap sales	299,540	5,438,116
	Others	2,652	-
		44,686,843	21,606,797
		332,611,911	326,802,720

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

		Un-audited			
		Nine Months Ended 30 September		Three Months Ended 30 September	
		2025	2024	2025	2024
		----- (Rupees) -----			
16	EARNINGS PER SHARE				
	Profit for the period - (Rupees)	2,628,390,432	2,360,050,329	1,001,079,479	858,798,932
	Weighted average number of ordinary shares outstanding during the period - (Numbers)	52,983,363	52,983,363	52,983,363	52,983,363
	Basic and diluted - (Rupees)	49.61	44.54	18.89	16.21

17. RELATED PARTY TRANSACTIONS

The related parties of the Company comprise subsidiary, associated companies, companies in which directors are interested, staff retirement funds and directors and key management personnel. The Company carries out transactions with various related parties. Significant transactions and balances with related parties that were not disclosed elsewhere are as follows:

17.1 Transactions during the period:

		(Un-audited) Nine Months Ended 30 September	
		2025	2024
		----- (Rupees) -----	
Name of related party	Nature of transaction		
Associates / related parties	Purchases	126,731,290	98,257,611
	Purchase Returns	5,270,993	-
	Dividend paid	202,575,520	256,570,993
	Interest income on loan	3,997,055	305,142
	Loan to subsidiary	125,000,000	-
	Receipts during the period	4,736,913	-
	Receipt against loan repayment	-	10,000,000
	Equity investment	125,000,000	-
	Contribution to employee benefit funds	156,282,616	71,861,594
	Remuneration of chief executive and executives	878,486,750	729,696,846

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

18. FINANCIAL RISK MANAGEMENT

18.1 Financial risk factors

The Company's financial risk management objectives and policies are consistent with that disclosed in the annual unconsolidated financial statements of the Company for the year ended December 31, 2024.

18.2 Fair values of financial assets and liabilities

There is no change in the nature and corresponding hierarchies of fair valuation levels of financial instruments from those as disclosed in the audited unconsolidated financial statements of the Company for the year ended December 31, 2024.

19. CORRESPONDING FIGURES

Corresponding figures have been re-arranged where necessary for the purpose of comparison, however, no significant re-classification or re-arrangements have been made in these unconsolidated condensed interim financial statements except for the following.

20. NON ADJUSTING EVENT AFTER THE BALANCE SHEET DATE

These are no significant reportable event after the unconsolidated condensed interim statement of financial position.

21. DATE OF AUTHORIZATION OF ISSUE

The Board of Directors of the Company authorized these unconsolidated condensed interim financial statements for issuance on 28 October 2025.



Dr. Adeel Abbas Haideri
Chief Executive Officer



Taufiq Ahmed Khan
Director



Ashfaq P. Alidina
Chief Financial Officer



Consolidated Condensed Interim Financial Statements

Highnoon Laboratories Limited
for the nine months ended 30 September 2025

Condensed Interim Consolidated Statement of Financial Position As at 30 September 2025 (Un Audited)

		Un Audited September 30 2025	Audited 31 December 2024
Note		----- (Rupees) -----	
ASSETS			
Non-current assets			
Property, plant and equipment	5	4,186,907,088	3,915,194,250
Intangible assets		45,783,439	46,866,785
Goodwill		834,230	834,230
Long-term deposits		49,384,996	25,566,894
Long-term advances		48,952,842	65,250,481
		4,331,862,595	4,053,712,640
Current assets			
Stock in trade	6	6,043,687,622	4,717,791,824
Trade receivables	7	4,083,792,865	2,423,596,428
Advances, trade deposits and prepayments		1,033,591,520	553,381,259
Other receivables		34,452,905	137,574,581
Short-term investment	8	1,368,326,411	3,638,850,646
Tax refunds due from the Government		305,814,152	212,310,027
Cash and bank balances	9	852,884,539	1,493,747,356
		13,722,550,013	13,177,252,121
TOTAL ASSETS		18,054,412,609	17,230,964,761


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director


Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Financial Position As at 30 September 2025 (Un Audited)

		Un Audited September 30 2025	Audited 31 December 2024	
Note		----- (Rupees) -----		
EQUITY AND LIABILITIES				
Share capital and reserves				
Authorized share capital				
100,000,000 (December 31, 2024: 100,000,000)				
	Ordinary shares of Rs. 10 each	1,000,000,000	1,000,000,000	
	Issued, subscribed and paid up share capital	10	529,833,630	529,833,630
	Capital reserve			
	Surplus on revaluation of property, plant and equipment - net of tax		1,050,297,557	1,077,558,758
	Revenue reserves			
	Accumulated profit		10,776,215,798	10,187,737,871
	Total Equity		12,356,346,985	11,795,130,259
LIABILITIES				
Non-current liabilities				
	Lease liabilities		247,469,324	70,062,585
	Long-term loan - secured	11	3,397,567	318,819,789
	Deferred tax liabilities - net		279,379,302	279,379,302
	Deferred liabilities		163,420,328	403,793,433
			693,666,521	1,072,055,109
Current liabilities				
	Trade and other payables		3,717,777,747	2,928,365,523
	Contract liabilities		298,134,369	244,683,677
	Unclaimed dividend		304,677,160	210,193,857
	Current portion of long-term liabilities		74,500,607	196,306,054
	Provision for taxation		557,931,343	-
	Short term borrowings		51,377,877	784,230,282
			5,004,399,103	4,363,779,393
CONTINGENCIES AND COMMITMENTS				
		12		
TOTAL EQUITY AND LIABILITIES			18,054,412,609	17,230,964,761

The annexed notes from 1 to 21 form an integral part of these consolidated condensed interim financial statements.


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director



Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Profit or Loss (Un Audited)


For the nine months ended 30 September 2025

		Nine Months Ended 30 September		Three Months Ended 30 September	
	Note	2025	2024	2025	2024
		----- (Rupees) -----		----- (Rupees) -----	
Revenue from contracts					
with customers- net	13	20,303,535,064	18,323,926,014	6,903,747,284	6,285,302,864
Cost of revenue	14	(9,105,173,204)	(9,158,641,472)	(3,131,785,320)	(3,097,258,629)
Gross Profit		11,198,361,860	9,165,284,542	3,771,961,964	3,188,044,235
Distribution, selling and promotional expenses		(5,749,295,626)	(4,802,571,591)	(2,125,588,729)	(1,789,452,975)
Administrative and general expenses		(1,201,854,957)	(817,826,641)	(439,552,054)	(284,677,190)
Other operating expenses		(231,960,070)	(320,025,511)	(41,514,029)	(99,757,408)
		(7,183,110,653)	(5,940,423,743)	(2,606,654,812)	(2,173,887,573)
Profit from operations		4,015,251,207	3,224,860,799	1,165,307,152	1,014,156,662
Other income	15	323,970,885	332,786,272	94,859,640	124,474,964
Finance costs		(101,030,033)	(177,373,324)	(41,766,847)	(62,360,854)
Profit before income tax and final tax		4,238,192,059	3,380,273,747	1,218,399,945	1,076,270,772
Final taxes		-	(10,178,417)	-	14,000,210
Profit before income tax		4,238,192,059	3,370,095,330	1,218,399,945	1,090,270,982
Taxation		(1,557,640,813)	(974,239,769)	(487,947,018)	(301,041,316)
Profit after tax for the period		2,680,551,246	2,395,855,561	730,452,927	789,229,666
Earnings per share - basic and diluted	16	50.59	45.22	13.79	14.90

The annexed notes from 1 to 21 form an integral part of these consolidated condensed interim financial statements.


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director


Ashfaq P. Alidina
Chief Financial Officer

**Condensed Interim Consolidated
Statement of Comprehensive Income (Un Audited)**
For the nine months ended 30 September 2025

	Nine Months Ended 30 September		Three Months Ended 30 September	
	2025	2024	2025	2024
	------(Rupees) -----		------(Rupees) -----	
Profit after tax for the period	2,680,551,246	2,395,855,561	730,452,927	789,229,666
Other comprehensive income				
Remeasurement loss on gratuity	-	-	-	-
Related deferred tax	-	-	-	-
Effect of deferred tax due to change in effective tax rate	-	-	-	-
Total comprehensive income for the period	2,680,551,246	2,395,855,561	730,452,927	789,229,666

The annexed notes from 1 to 21 form an integral part of these consolidated condensed interim financial statements.



Dr. Adeel Abbas Haideri
Chief Executive Officer



Taufiq Ahmed Khan
Director



Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Cash Flow (Un Audited)

For the nine months ended 30 September 2025

	Nine Months Ended 30 Septemebr	
	2025	2024
Note	----- (Rupees) -----	
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before income tax	4,238,192,059	3,380,273,747
Adjustments for non cash and other items:		
Depreciation of property, plant and equipment	253,473,356	184,566,462
Depreciation of right-of-use asset	11,576,481	69,757,320
Amortization of intangible assets	11,290,984	20,415,884
Gain on disposal of property plant and equipment	(35,502,805)	(16,280,682)
Exchange (gain) / loss - net	(2,066,989)	(5,027,675)
Dividend income on short-term investment	(10,676,633)	(199,239,803)
Provision for slow moving and obsolete stocks	7,685,497	(14,059,223)
Provision for defined benefit obligation	376,528,691	45,222,248
Provision for Workers' Profit Participation fund	216,175,371	148,691,874
Provision for Workers' Welfare Fund	81,643,395	3,433,555
Provision for Central Research Fund	37,970,119	55,121,106
Allowance for expected credit losses	-	26,445,800
Finance costs	101,030,033	177,678,466
	1,049,127,500	496,725,332
Profit before working capital changes	5,287,319,559	3,876,999,079
Working capital changes:		
(Increase) / decrease in current assets:		
Inventories	(1,333,581,295)	540,126,065
Trade debts	(1,658,129,448)	(1,092,526,032)
Advances, trade deposits and prepayments	(480,210,261)	(455,290,284)
Other receivables	103,121,676	(14,938,761)
Tax refunds due from the Government	(93,504,125)	172,861,151
Increase / (decrease) in current liabilities:		
Trade and other payables	535,421,526	532,460,363
Contract liabilities	53,450,692	963,967,708
	(2,873,431,235)	646,660,210
Cash generated from operations	2,413,888,324	4,523,659,289
Income taxes paid	(999,709,470)	(733,234,750)
Gratuity paid	(616,901,796)	(59,570,043)
Finance costs paid	(101,030,033)	(177,677,501)
Workers' Welfare Fund paid	(81,798,187)	-
Central research fund paid	-	(36,451,075)
	(1,799,439,486)	(1,006,933,369)
Net cash flows from operating activities	A 614,448,838	3,516,725,920

Condensed Interim Consolidated Statement of Cash Flow (Un Audited)

For the nine months ended 30 September 2025

		Nine Months Ended 30 Septemebr	
	Note	2025	2024
------(Rupees)-----			
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(618,274,235)	(560,942,971)
Purchase of intangible assets		(10,207,638)	(17,341,759)
Decrease / (Increaease) in long term advances		16,297,639	(26,706,821)
Short term investments - net		2,270,524,235	(40,931,730)
Long term deposits - net		(23,818,102)	(2,037,943)
Dividend income on short term investments		10,676,633	-
Proceeds from disposal of property plant and equipment		117,014,365	46,212,227
Net cash generated from investing activities	B	1,762,212,897	(601,748,997)
CASH FLOWS FROM FINANCING ACTIVITIES			
Lease liabilities - net		180,601,292	(199,344,194)
Long term loan - net		(440,422,222)	(34,172,222)
Dividend paid		(2,024,851,217)	(1,567,428,771)
Net cash used in financing activities	C	(2,284,672,147)	(1,800,945,187)
Net increase in cash and cash equivalents	(A+B+C)	91,989,588	1,114,031,736
Cash and cash equivalents at beginning of the period		709,517,074	(47,821,733)
Cash and cash equivalents at end of the period	9.2	801,506,662	1,066,210,003

The annexed notes from 1 to 21 form an integral part of these consolidated condensed interim financial statements.


Dr. Adeel Abbas Haideri
Chief Executive Officer


Taufiq Ahmed Khan
Director


Ashfaq P. Alidina
Chief Financial Officer

Condensed Interim Consolidated
Statement of Changes in Equity (Un Audited)
For the nine months ended 30 September 2025

	Issued, sub- scribed and paid-up capital	Capital Reserves	Revenue reserves			Total
		Revaluation Surplus on operating fixed assets	General reserve	Accumulated profit	Sub total	
----- Rupees -----						
Balance as at January 01, 2024 - (audited)	529,833,630	1,125,838,302	114,000,000	8,265,976,617	8,379,976,617	10,035,648,549
Total comprehensive income for the period ended September 30, 2024	-	-	-	2,395,855,561	2,395,855,561	2,395,855,561
Surplus transferred to accumulated profit						
Incremental depreciation relating to surplus on revaluation - net of tax	-	(45,313,277)	-	45,313,277	45,313,277	-
Transaction with owners, recorded directly in equity						
Final dividend @ Rs. 30 per share for the year ended December 31, 2023	-	-	-	(1,589,500,894)	(1,589,500,894)	(1,589,500,894)
Balance as at September 30, 2024 - (un-audited)	529,833,630	1,080,525,025	114,000,000	9,117,644,561	9,231,644,561	10,842,003,216
Balance as at January 01, 2025 - (audited)	529,833,630	1,077,558,758	114,000,000	10,073,737,871	10,187,737,871	11,795,130,259
Total comprehensive income for the period ended September 30, 2025	-	-	-	2,680,551,246	2,680,551,246	2,680,551,246
Surplus transferred to accumulated profit						
Incremental depreciation relating to surplus on revaluation - net of tax	-	(27,261,201)	-	27,261,201	27,261,201	-
Transaction with owners, recorded directly in equity						
Final dividend @ Rs. 40 per share for the year end December 31, 2024	-	-	-	(2,119,334,520)	(2,119,334,520)	(2,119,334,520)
Balance as at September 30, 2025 - (un-audited)	529,833,630	1,050,297,557	114,000,000	10,662,215,798	10,776,215,798	12,356,346,985

The annexed notes from 1 to 21 form an integral part of these consolidated condensed interim financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq P. Alidina
Chief Financial Officer

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

1. CORPORATE INFORMATION

The Highnoon Group ("the Group") comprises of Highnoon Laboratories Limited ("HNL") ("the Holding Company") and Curexa Health (Private) Limited ("CHL") ("the Subsidiary Company").

- 1.1 Highnoon Laboratories Limited ("the Holding Company") was incorporated in Pakistan under the Companies Act, 2017 ("the Act") and its shares are quoted on Pakistan Stock Exchange since November 1994. The Group is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and allied consumer products. The registered office of the Group is situated at 17.5 KM, Multan Road, Lahore.

The Subsidiary Company was incorporated with the principle object to carry on business as manufacturer, importer and dealers of all kinds of pharmaceutical.

Geographical location and addresses of major business units of the Group are as under:

Business Units	Geographical Location	Address
Registered office / Manufacturing facility	Lahore	17.5 KM, Multan Road, Lahore
Corporate Office	Lahore	Office# 901 Tricon Corporate Centre, Jail Road, Lahore.
Subsidiary Registered office/ Manufacturing facility	Lahore	517- Sundar Industrial Estate, Raiwind, Lahore
Sales office	Karachi	202 Anam Empire, Block 7/8 KCHS,Shahrah e Faisal, Karachi
Sales office	Lahore	14-G, Block L, Gulberg - III, Lahore
Sales office	Rawalpindi	132 Hali Road, Westridge - I, PeshawarRoad, Rawalpindi

2. BASIS OF PREPARATION

2.1 Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. These accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Financial Reporting Standard (IFRS) issued by the International Accounting Standard Board (IASB) as notified under the Act and Islamic Financial Accounting Standard (IFAS) as issued by ICAP; and
- Provision and directives issued under the Act.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

- 2.2 These consolidated condensed interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with consolidated financial statements of the Group for the year ended December 31, 2024. Comparative consolidated condensed interim statement of financial position is stated from annual audited consolidated financial statements as of December 31, 2024, whereas comparatives for consolidated condensed interim statement of profit or loss and other comprehensive income, consolidated condensed interim statement of changes in equity and consolidated condensed interim statement of cash flows are extracted from consolidated condensed interim financial statements of the Group for the nine months ended September 30, 2024.
- 2.3 The consolidated condensed interim financial statements have been prepared under the historical cost convention, except for certain classes of operating fixed assets (as mentioned in consolidated financial statements of the Group for the year ended December 31, 2024) and certain employees' retirement benefits which are measured at revalued amounts and present value, respectively. These consolidated condensed interim financial statements are prepared in Pak Rupees, which is the functional currency of the Group. Figures have been rounded off to the nearest Pak rupee unless otherwise stated.

3 USE OF ESTIMATES AND JUDGEMENTS

The preparation of these consolidated condensed interim financial statements, in conformity with accounting and reporting standards as applicable in Pakistan requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Actual results may differ from the estimates. During the preparation of these consolidated condensed interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation and assumptions are consistent with those that were applied to the audited consolidated financial statements of the Group for the year ended December 31, 2024.

4 MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies adopted in the preparation of these consolidated condensed interim financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2024 except for the policies mentioned and the adoption of amendments to approved accounting and reporting standards as applicable in Pakistan which became effective for the current period as disclosed in Note 4.1 to these consolidated condensed interim financial statements. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

4.1 Changings in accounting standard interpretations and pronouncements

a) New standards, interpretations, amendments and improvements effective during current period

Certain standards, amendments and interpretations to approved accounting standards are effective for accounting periods beginning on January 01, 2025, but are considered not to be relevant or to have any significant effect on the Group's operations (although they may affect the accounting for future transactions and events) and are, therefore, not detailed in these consolidated condensed interim financial statements.

b) Standards, interpretation and amendments to approved accounting standards that are not yet effective

In addition to the above standards and amendments, improvements to various accounting standards and conceptual framework have also been issued by the IASB. Such improvements are generally effective for accounting periods beginning on or after January 01, 2025. The Group expects that such improvements to the standards will not have any material impact on the Group's consolidated condensed interim financial statements in the period of initial application.

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		------(Rupees) -----	
5. PROPERTY, PLANT AND EQUIPMENT			
Operating fixed assets :			
Owned assets	5.1	3,560,626,851	3,624,780,882
Right of use assets	5.1	251,333,384	89,084,423
		3,811,960,235	3,713,865,305
Capital work-in-progress	5.1	356,731,379	177,078,595
Advances against capital assets		18,215,474	24,250,350
		4,186,907,088	3,915,194,250

		Operating owned fixed assets	Right of use assets	Capital work in progress
5.1	Opening	3,624,780,882	89,084,423	177,078,595
	Additions	227,805,197	216,851,130	329,923,752
	Transfers/Disposals	(38,485,871)	(43,025,688)	(150,270,968)
	Depreciation for the Period	(253,473,356)	(11,576,481)	-
		3,560,626,851	251,333,384	356,731,379

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		------(Rupees) -----	
6 STOCK IN TRADE			
Raw materials:			
In hand		2,965,454,872	2,133,024,020
In transit		920,022,970	161,515,778
With third party		171,145,230	158,952,120
		4,056,623,072	2,453,491,918
 Packing material		859,592,859	841,317,571
Stores, spare parts and loose tools		179,554,429	96,830,205
 Work in process		460,973,970	661,726,187
 Finished goods:			
Trading -in hand		406,292,681	97,630,343
Manufactured		300,486,668	778,946,160
		706,779,349	876,576,503
		6,263,523,679	4,929,942,384
Less: Provision for slow moving and obsolete items		(219,836,057)	(212,150,560)
		6,043,687,622	4,717,791,824
7 TRADE RECEIVABLES			
Foreign		103,410,306	120,550,269
Local		4,038,034,063	2,360,697,663
		4,141,444,369	2,481,247,932
Less: allowance for expected credit losses (ECL)	7.1	(57,651,504)	(57,651,504)
		4,083,792,865	2,423,596,428
7.1 Allowance for expected credit losses			
Opening balance		57,651,504	22,372,807
Charged during the period / year		-	35,278,697
		57,651,504	57,651,504

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

7.1.1 The impact of ECL for the period is insignificant, hence, no allowance is made during the period.

		Un Audited 30 September 2025	Audited 31 December 2024
	Note	------(Rupees) -----	
8	SHORT-TERM INVESTMENT		
	Investments at fair value through profit or loss		
	Mutual funds - fair value through profit and loss	8.1 1,176,150,455	3,471,920,933
	Term deposit receipts - at amortization cost	8.2 192,175,956	166,929,713
		1,368,326,411	3,638,850,646

8.1 Set out below is the movement during the period / year:

Balance at the beginning of the period / year	3,471,920,933	1,699,124,325
Additions during the period / year	2,708,921,850	4,383,230,301
Redemption during the period / year	(5,248,178,117)	(2,847,386,088)
Realized gain on redemption of investment during the period / year	84,043,829	79,159,430
Un-realized (loss) / gain on remeasurement of investments during the period / year	159,441,960	157,792,965
Closing fair value of short-term investment	1,176,150,455	3,471,920,933

8.2 These represents investments in term deposit receipts. They carry average profit at the rate of ranging from 10.00% - 16.00% (December 31, 2024: 11.25% - 21.00%) with maturity up to November 22, 2025.

		Un Audited 30 September 2025	Audited 31 December 2024
	Note	------(Rupees) -----	
9	CASH AND BANK BALANCES		
Cash and imprest		906,439	633,770
Cash as banks:			
Current accounts			
-Local currency		130,369,529	1,035,370,000
-Foreign currency		155,715,662	75,337,262
		286,085,191	1,110,707,262
Saving accounts	9.1	565,892,908	382,406,324
		852,884,539	1,493,747,356

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

9.1 These represent saving accounts which carry average profit at the rate ranging from 6.46% to 9.00% (December 31, 2024: 9.21% to 20.10%).

9.2 Cash and cash equivalents

The above figures of cash and bank balances reconcile to the amount of cash and cash equivalents shown in the statement of cashflows at the end of financial year as follows:

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		----- (Rupees) -----	
Cash and bank balances		852,884,539	1,493,747,356
Short term borrowings		(51,377,877)	(784,230,282)
Cash and cash equivalents as per statement of cashflows		801,506,662	709,517,074
10 ISSUED, SUBSCRIBED AND PAID UP SHARE CAPITAL			
5,905,000 (December 31, 2024: 5,905,000) ordinary shares of Rs. 10 each fully paid in cash		59,050,000	59,050,000
95,000 (December 31, 2024: 95,000) ordinary shares of Rs.10 each issued for consideration other than cash		950,000	950,000
46,983,363 (December 31, 2024: 46,983,363) ordinary shares of Rs. 10 each issued as bonus shares		469,833,630	469,833,630
		529,833,630	529,833,630
11 LONG-TERM LOAN - SECURED			
Long-term loan		7,293,863	447,716,085
Less: Current portion shown under current liabilities		(3,896,296)	(128,896,296)
		3,397,567	318,819,789
11.1 The movement of Long-term loan is as follows:			
Opening balance	11.1.1 & 11.1.2	447,716,085	714,112,381
Addition during the period / year:		-	-
Loan obtained during the period / year		-	-
Less: deferred grant recognized		-	-
Principal payments made during the period / year		(440,422,222)	(266,396,296)
		7,293,863	447,716,085
Current portion shown under current liabilities		(3,896,296)	(128,896,296)
Closing balance		3,397,567	318,819,789

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

- 11.1.1** This includes loan from Meezan Bank Limited taken in year 2023 to meet the long term financing needs having sanctioned limit of Rs. 500 million and carries markup at the rate of 3 month KIBOR + 0.1% per annum payable quarterly, whereas the principal is repayable in 16 equal quarterly instalments commenced after a grace period of one year from September 2024. This facility is secured against first pari passu charge over all present and future plant and machinery. This loan has been early settled and repaid in full in current period.
- 11.1.2** This includes loan obtained from MCB Bank Limited under facility for setting up solar based power project under SBP financing scheme for renewable Energy having sanctioned limit of Rs. 50 million (2024: Rs. 50 million) and carries markup at the rate of 2% + 0.5% per annum payable quarterly (2024: 2% + 0.5%) whereas principal is repayable in 27 equal quarterly instalments starting from December 10, 2022. This facility is secured against lien on mutual fund up to Rs. 67 million placed in MCB-Arif Habib Savings and Investment Limited. The loan has been measured at its fair value in accordance with IFRS 9 (Financial Instruments) using effective interest rate of 3M KIBOR at respective draw down date. The difference between fair value of loan and loan proceeds has been recognised as deferred grant as per requirements of IAS 20 (Accounting for Government grants and disclosure of Government assistance) and as per Circular 11/2020 issued by the Institute of Chartered Accountants of Pakistan.

12. CONTINGENCIES AND COMMITMENTS

12.1 Contingencies

There have been no significant changes in other contingencies as reported in the annual audited consolidated financial statements of the Group for the year ended December 31, 2024 except as follow:

- 12.1.1** The Assistant Commissioner Inland Revenue ('ACIR') has issued an order dated June 30, 2025 u/s 122 of the Income Tax Ordinance, 2001, in respect of tax year 2019, creating a demand amounting to Rs. 845.706 million. The Group has preferred an appeal before Commissioner Inland Revenue, Appeals ('CIR(A)') against this order, on July 26, 2025, which is pending adjudication. The provision has not been recognised by the Group, as the management expects a favourable outcome.
- 12.1.2** There are several claims that have been lodged against the Group. The quantum of potential liability cannot be estimated reliably. The Group is hopeful of a favorable outcome, therefore, no provision has been recognized in these consolidated condensed interim financial statements.

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

	Note	Un Audited 30 September 2025	Audited 31 December 2024
		----- (Rupees) -----	
12.2 Commitments			
Commitments against irrevocable letters of credit include:			
Letter of credit		1,640,697,030	1,032,325,783
Bank contracts		709,545,816	270,379,501
Ijarah Rentals	12.2.1	88,956,224	-
		2,439,199,070	1,302,705,284

13. REVENUE FROM CONTRACTS WITH CUSTOMERS- NET

13.1 Disaggregated revenue information

Set out below is the disaggregation of the Group's revenue from contracts with customers :

	Un-audited			
	Nine Months Ended 30 September		Three Months Ended 30 September	
	2025	2024	2025	2024
	----- (Rupees) -----			
Trading and manufactured products:				
Local	22,318,612,784	20,313,979,826	7,855,598,126	6,377,084,501
Export	1,536,117,458	1,551,914,719	676,015,467	577,913,626
	23,854,730,242	21,865,894,545	8,531,613,593	6,954,998,128
Toll manufacturing	614,707,380	516,422,734	243,504,514	175,082,401
Less:				
Sales tax	(199,213,692)	(197,121,595)	(71,453,064)	(75,910,322)
Sales return	(501,171,741)	(550,414,985)	(236,351,063)	(96,340,186)
Trade discount	(3,465,517,127)	(3,310,854,685)	(1,563,566,696)	(672,527,156)
	20,303,535,064	18,323,926,014	6,903,747,284	6,285,302,864

**Notes to the Condensed Interim
Consolidated Financial Statements (Un Audited)**
For the nine months ended 30 September 2025

	Un-audited Nine Months Ended 30 September	
	2025	2024
	------(Rupees)-----	
13.2 Geographical information		
Pakistan	18,767,984,858	16,772,011,293
Afghanistan	1,138,469,885	1,146,988,341
Cambodia	18,883,757	10,808,449
France	69,098,735	128,716,059
Gambia	-	2,029,002
Iraq	14,069,700	40,880,365
Kenya	6,177,926	55,914,476
Mauritius	1,052,637	1,919,209
Somalia	4,435,437	2,855,626
Sri Lanka	70,701,337	34,843,782
Sudan	15,668,514	8,274,295
Tajikistan	-	3,678,444
Tanzania	-	4,503,993
Turkmenistan	14,260,472	-
United Arab Emirates	177,414,849	102,588,943
Zambia	5,316,958	7,913,737
	20,303,535,064	18,323,926,014

	Un-audited			
	Nine Months Ended 30 September		Three Months Ended 30 September	
	2025	2024	2025	2024
	------(Rupees)-----			
14. COST OF REVENUE				
Opening stock of finished goods	876,576,503	960,932,694	563,731,499	327,824,635
Cost of goods manufactured	8,094,333,342	7,993,900,960	3,012,864,484	2,882,251,947
Purchased finish products	841,042,708	725,414,742	261,968,686	215,566,402
Available stock for sale	9,811,952,553	9,680,248,396	3,838,564,669	3,425,642,984
Closing stock of finished goods	(706,779,349)	(521,606,924)	(706,779,349)	(328,384,355)
Cost of sales	9,105,173,204	9,158,641,472	3,131,785,320	3,097,258,629

**Notes to the Condensed Interim
Consolidated Financial Statements (Un Audited)**
For the nine months ended 30 September 2025

Un-audited Nine Months Ended 30 September	
2025	2024
----- (Rupees) -----	

15. OTHER INCOME

Income from financial assets:

Return on deposits	9,061,172	11,088,946
Profit on term deposit receipts	21,477,305	59,432,166
Dividend income on short-term investment	10,676,633	199,239,803
Unrealized gain on re-measurement of short term investment to fair value	159,441,960	-
Realized gain on redemption of short term investment	84,043,829	35,170,175
Exchange gain - net	2,066,989	6,136,384
	286,767,888	311,067,474

Income from non-financial assets:

Gain on disposal of property, plant and equipment	35,502,805	16,280,682
Royalty income from subsidiary	-	-
Scrap sales	1,697,540	5,438,116
Others	2,652	-
	37,202,997	21,718,798
	323,970,885	332,786,272

Un-audited			
Nine Months Ended 30 September		Three Months Ended 30 September	
2025	2024	2025	2024
----- (Rupees) -----			

16. EARNINGS PER SHARE

Profit for the period - (Rupees)	2,680,551,246	2,395,855,561	730,452,927	789,229,666
----------------------------------	---------------	---------------	-------------	-------------

Weighted average number of
ordinary shares outstanding during
the period - (Numbers)

52,983,363	52,983,363	52,983,363	52,983,363
------------	------------	------------	------------

Basic and diluted - (Rupees)	50.59	45.22	13.79	14.90
------------------------------	-------	-------	-------	-------

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

17 RELATED PARTY TRANSACTIONS

The related parties of the Group comprise associated companies, companies in which directors are interested, staff retirement funds and directors and key management personnel. The Group carries out transactions with various related parties. Significant transactions and balances with related parties that were not disclosed elsewhere are as follows:

17.1 Transactions during the period:

		(Un-audited) Nine Months Ended 30 September	
		2025	2024
		------(Rupees)-----	
Name of related party	Nature of transaction		
Associates / related parties	Purchases	-	32,567,488
	Purchase Returns	5,270,993	-
	Dividend paid	202,575,520	256,570,993
	Contribution to employee benefit funds	167,335,813	75,879,337
	Remuneration of chief executive and executives	878,486,750	777,063,291

18. FINANCIAL RISK MANAGEMENT

18.1 Financial risk factors

The Group's financial risk management objectives and policies are consistent with that disclosed in the annual consolidated financial statements of the Group for the year ended December 31, 2024.

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For the nine months ended 30 September 2025

18.2 Fair values of financial assets and liabilities

There is no change in the nature and corresponding hierarchies of fair valuation levels of financial instruments from those as disclosed in the audited consolidated financial statements of the Group for the year ended December 31, 2024.

19. CORRESPONDING FIGURES

Corresponding figures have been re-arranged where necessary for the purpose of comparison, however, no significant re-classification or re-arrangements have been made in these consolidated condensed interim financial statements.

20. NON ADJUSTING EVENT AFTER THE BALANCE SHEET DATE

These are no significant reportable event after the consolidated condensed interim statement of financial position.

21. DATE OF AUTHORIZATION OF ISSUE

The Board of Directors of the Group authorized these consolidated condensed interim financial statements for issuance on 28 October 2025.



Dr. Adeel Abbas Haideri
Chief Executive Officer



Taufiq Ahmed Khan
Director



Ashfaq P. Alidina
Chief Financial Officer



Highnoon

Address : 17.5 KM, Multan Road,
Lahore - 53700, Pakistan.

UAN : +92 (42) 111-000-465

Phone : +92 (42) 37510023-27

Fax : +92 (42) 37510037

Email : info@highnoon.com.pk

Web : www.highnoon-labs.com